(Q33875221)

English

Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

0 references

multicenter clinical trial

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

diabetic polyneuropathy

1 reference

based on heuristic

inferred from title

author name string

Reljanovic M

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Reichel G

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Rett K

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Lobisch M

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Schuette K

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Möller W

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Tritschler HJ

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Mehnert H

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

1 September 1999

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Free Radical Research

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

171-179

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Growth factors and diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy.

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Role of oxidative stress in development of complications in diabetes

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid.

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Tolrestat for Mild Diabetic Neuropathy: A 52-Week, Randomized, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1080%2F10715769900300721

21 January 2018

Identifiers

10.1080/10715769900300721

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33875221&oldid=1629094453"